Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBE Therapeutics AG

www.nbe-therapeutics.com

Latest From NBE Therapeutics AG

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather

Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.

Financing StartUps and SMEs

SOTIO Aims To Become A Diverse Oncology Company

Cancer vaccine development is not the only R&D avenue being pursued by the Czech Republic-based biotech, SOTIO, which is aiming to become a fully-integrated biopharma company.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • NBE Therapeutics AG
  • Senior Management
  • Ulf Grawunder, PhD, CEO
    Roger R Beerli, PhD, CSO
  • Contact Info
  • NBE Therapeutics AG
    Phone: 61 633 2230
    Hochbergerstrasse 60C
    Tech Park Basel
    Basel, CH-4057
    Switzerland
UsernamePublicRestriction

Register